Tiziana Life Sciences Stock (NASDAQ: TLSA)

Tiziana Life Sciences

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

bz_pharma_briefs

Biotech

News

Health Care

General

TLSA

Tiziana Life Sciences recently discovered new immune biomarkers in SPMS patients treated with nasal foralumab.

Neurology-Focused Tiziana Life Confirms Discovery In Multiple Sclerosis Therapy Study

Wall Street

Equities

Market Summary

Economics

Federal Reserve

Pre-Market Outlook

Markets

BMBL

LFCR

ONDS

SPSC

TSLA

U.S. stock futures were higher on Friday, the slipping in first trading session of 2025. All four index futures advanced in premarket trade.

US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus

Elon Musk Predicts AI Will Match Human Capabilities In Few Years- 'The Cup Is 80% Full...Maybe 90%'

Tesla Inc (NASDAQ: TLSA) and SpaceX, chief executive officer, Elon Musk sparked a new controversy by saying that Jeff Bezos, the founder and executive chairman of Amazon.com, predicted President-elect Donald Trump&#39;s defeat and asked people to sell stake in Musk&#39;s companies, before the election.

Elon Musk Says Amazon Founder Jeff Bezos Urged Tesla, SpaceX Investors To Dump Stakes, Predicting Trump&#39;s Loss

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences Ltd

Press Releases

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Alector

Coherus BioSciences

Cellectis S.A. - American Depositary Shares

Cellectis

Elicio Therapeutics

Elutia

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

Immunic

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Seres Therapeutics

Macrogenics

Molecular Partners AG - American Depositary Shares

Molecular Partners

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Instil Bio

Vaxart

Zentalis Pharmaceuticals, Inc. - common stock

Comments

Tiziana Life Sciences

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga